DECASPRAY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DECASPRAY (DECASPRAY).
Decaspray contains dexamethasone, a potent synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene transcription. This results in anti-inflammatory and immunosuppressive effects through inhibition of phospholipase A2, reduction of prostaglandin and leukotriene synthesis, suppression of cytokine production, and decreased capillary permeability.
| Metabolism | Dexamethasone is metabolized primarily in the liver via cytochrome P450 3A4 (CYP3A4) to inactive metabolites. |
| Excretion | Decaspray (dexamethasone) is primarily metabolized in the liver, with less than 10% excreted unchanged in urine. Minor biliary excretion occurs, but fecal elimination is negligible. Overall, renal excretion accounts for >90% as metabolites, with <10% as parent drug. |
| Half-life | The terminal elimination half-life is approximately 3-4 hours in adults. This short half-life is consistent with its classification as a long-acting glucocorticoid due to high potency and prolonged tissue effects, not extended plasma presence. |
| Protein binding | Approximately 77% bound to serum proteins, primarily albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | Volume of distribution is approximately 0.8 L/kg (range 0.5-1.0 L/kg). This indicates moderate distribution into tissues, with higher penetration into CNS compared to other glucocorticoids. |
| Bioavailability | Oral bioavailability is approximately 80-90%. Intramuscular bioavailability is nearly 100% due to complete absorption. Intranasal bioavailability is low (<1%) due to local administration, but systemic absorption can occur with high doses. |
| Onset of Action | Intravenous: rapid, within minutes; intramuscular: 1-2 hours; oral: 1-2 hours; intranasal: within 12 hours for maximal effect. |
| Duration of Action | Duration of adrenal suppression: 2.75 days after a single dose. Clinical anti-inflammatory effects persist for 24-48 hours after a single dose. Duration depends on dose and route; for acute conditions, single IV doses may provide effects for 24-72 hours. |
| Molecular Weight | 380.459 |
2-4 metered sprays (400-800 mcg) intranasally twice daily. Maximum 8 sprays (1600 mcg) per day.
| Dosage form | AEROSOL |
| Renal impairment | No adjustment required for any degree of renal impairment. |
| Liver impairment | No adjustment required for Child-Pugh Class A or B. For Child-Pugh Class C, caution advised due to lack of data; monitor for systemic effects. |
| Pediatric use | Children 2-11 years: 1-2 sprays (200-400 mcg) intranasally twice daily. Maximum 4 sprays per day. |
| Geriatric use | Same as adult dosing. No specific dose reduction required; monitor for adrenal suppression in prolonged use. |
| 1st trimester | Avoid due to potential teratogenicity; insufficient human data. |
| 2nd trimester | Use only if clearly needed; monitor fetal growth. |
| 3rd trimester | Avoid near term; may cause neonatal adrenal suppression. |
Clinical note
Comprehensive clinical and safety monograph for DECASPRAY (DECASPRAY).
| Placental transfer | Crosses placenta; approximately 60% of maternal serum concentration. |
| Breastfeeding | Excreted in breast milk; use with caution. Monitor infant for adrenal suppression. |
| Lactation Rating | L3 (Moderately Safe) |
■ FDA Black Box Warning
None
| Serious Effects |
Systemic fungal infectionHypersensitivity to betamethasone or any componentIntramuscular administration in idiopathic thrombocytopenic purpuraIntra-articular injection in unstable joints, infection, or bleeding diathesis
| Precautions | Topical corticosteroids may cause systemic absorption, leading to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria. Systemic absorption is increased with use on large surface areas, prolonged use, occlusive dressings, or in pediatric patients. Avoid use on face, groin, or axillae unless directed. Use caution in patients with bacterial, fungal, or viral skin infections; may mask or worsen infection. Discontinue if irritation or sensitization occurs. |
| Food/Dietary | No known food interactions. Avoid excessive intake of potassium-rich foods if prolonged use on large areas to mitigate risk of hypokalemia. |
Loading safety data…
| Teratogenic Risk | FDA Category C. First trimester: potential for orofacial clefts, though absolute risk low. Second/third trimester: risk of intrauterine growth restriction, oligohydramnios, and premature closure of ductus arteriosus with prolonged use. |
| Fetal Monitoring | Monitor blood pressure, blood glucose, and signs of infection in mother. Fetal: ultrasound for growth and amniotic fluid volume; fetal heart rate monitoring if used near term for potential ductus arteriosus constriction. |
| Fertility Effects | No known negative impact on fertility with short-term use; chronic high doses may disrupt menstrual cycle and ovulation. |
| Clinical Pearls | Decaspray (dexamethasone topical aerosol) is a potent corticosteroid for dermatologic use. Avoid use on infected skin without concurrent anti-infective therapy. Limit application to small areas and use sparingly to minimize systemic absorption. Do not use on face, groin, or axillae due to risk of atrophy. Discontinue if irritation or sensitization occurs. |
| Patient Advice | Apply a thin film only to affected skin areas as directed. · Do not cover the treated area with bandages unless instructed by your doctor. · Avoid contact with eyes, mouth, or open wounds. · Do not use on diaper rash or under diapers. · Wash hands after application unless treating hands. · Inform your doctor if condition worsens or does not improve after 2 weeks. · Do not use for other conditions without consulting a healthcare provider. |